Clinical Trials in AML Seek to Eliminate ‘Leftover’ Cells That Persist After Treatment

Over the last decade, significant strides have been made in understanding the molecular underpinnings of acute myelogenous leukemia (AML) in adults, which has led to better drugs and better treatment outcomes for patients. This shifting landscape now makes it possible for cancer researchers and providers to ask, “How can we do better?” Dana-Farber medical oncologist … Read more

Building In Access from the Start: Five Efforts by the Centers for Early Detection and Interception 

Dana-Farber’s Centers for Early Detection and Interception, founded in 2023, aim to detect cancer early, when there is a greater chance of treating and curing that cancer. The Centers also serve as a hub for research, with investigators seeking to better understand cancer risk and how it can be reduced.  “Dana-Farber has always been the … Read more

Study Highlights Unique Needs of Young Adults with Colorectal Cancer

Clinicians and researchers have recognized a disturbing trend in recent years: colorectal cancer (CRC) in young people is skyrocketing. In individuals under the age of 50, the incidence of CRC has increased about 2% each year since the 1990s, and, according to the American Cancer Society, is now the leading cause of death in males … Read more

Dana-Farber Researchers ‘Hijack’ Gut Bacteria to Design Novel Form of Cancer Immunotherapy

Tumors are experts at dodging the immune system. This evasion not only helps to ensure their survival, but also has important implications for treatment. That’s because cancer therapies that harness the immune system, such as CAR T-cells or other engineered immune cells, are often rendered ineffective by the milieu that surrounds a tumor — known … Read more

Study of Inherited Prostate Cancer Genetics in Africa Highlights Importance of Research

The genetic landscape of prostate cancer susceptibility in Africa is, like the continent itself, a picture of sweeping diversity, the largest study of the phenomenon concludes.  The findings, published in the journal Nature Genetics, are an important step in unravelling why prostate cancer rates are highest in men of African descent, whether they live in … Read more

Prostate Cancer Vaccines: What’s the Latest?   

Like all vaccines, prostate cancer vaccines work by stimulating the body’s immune system. Unlike vaccines for the flu, COVID-19 and other infections, which protect against disease, prostate cancer vaccines are a form of treatment.   Treatment vaccines activate the immune response against cancer cells by targeting antigens – cancer-related proteins produced in greater abundance in tumor … Read more

Researchers Uncover Key Actor in Spread of Breast Cancer to the Brain 

When breast cancer metastasizes, it often heads for the brain, where it can be exceptionally difficult to root out. The key to preventing the spread of the cancer, or thwarting it if it does reach the brain, is to understand the mechanism that turns stationary tumor cells into nomadic intruders.  In a recent study, a … Read more

Breast Cancer Disparities: What Is Dana-Farber Doing to Address Them?  

Overall survival of breast cancer has improved for everyone in the U.S. in recent years, but the pace isn’t the same for all groups of people. Some groups still experience dramatic disparities.   For example, according to the American Cancer Society:  Dana-Farber wants to close these gaps so that everyone benefits equally from high-quality care and … Read more

Dana-Farber’s Focus on Equity in Breast Cancer Clinical Research 

Clinical trials assess new medicines to ensure they are safe and effective and to find out which patients they are most likely to benefit.   However, clinical trials often enroll few people of color for a constellation of reasons related to historical marginalization of certain groups. Systemic marginalization can result in lower levels of income, fewer … Read more

Science Behind Targeted Drug for Pediatric Brain Cancer Has Dana-Farber Roots 

Dana-Farber researcher Charles Stiles, PhD, remembers the call. It was 2008 and a colleague phoned from a conference to deliver the news. Two separate research teams had discovered a genetic driver for the most common of childhood brain tumors called pediatric low-grade glioma. The problem of finding a genetic target to improve treatment for this … Read more

What’s the Latest Research in Lynch Syndrome?  

Lynch syndrome is an inherited condition that increases an individual’s risk for certain types of cancer. It’s caused by a mutation in any of five specific genes: MLH1, MSH2, MSH6, PMS2, and EPCAM.   People born with a mutation in one or more of these genes have a significantly increased risk of developing colorectal or uterine cancer and a somewhat … Read more

Bispecific Antibody Therapy for Lymphoma: What You Need to Know   

Bispecific antibody therapies are a type of immunotherapy for patients with B-cell non-Hodgkin lymphoma. These therapies provide a valuable new option for patients.  There are many standard therapies that are monoclonal antibodies. These therapies treat cancer by binding to a marker on cancer cells and rallying the immune system to destroy them.  Bispecific antibodies are … Read more

BCL2 Inhibitors: What’s the Latest Research?

BCL2 inhibitors are drugs that prompt cancer cells to die by altering the interactions among key proteins within the cells. They were clinically developed, in large part, by researchers at Dana-Farber and have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML) and chronic lymphocytic leukemia … Read more